Cynata Therapeutics Limited Stock Performance
| CYYNF Stock | USD 0.19 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Cynata Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cynata Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Cynata Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 26.7 M |
Cynata |
Cynata Therapeutics Relative Risk vs. Return Landscape
If you would invest 19.00 in Cynata Therapeutics Limited on September 12, 2024 and sell it today you would earn a total of 0.00 from holding Cynata Therapeutics Limited or generate 0.0% return on investment over 90 days. Cynata Therapeutics Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Cynata, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cynata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cynata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cynata Therapeutics Limited, and traders can use it to determine the average amount a Cynata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CYYNF |
Based on monthly moving average Cynata Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cynata Therapeutics by adding Cynata Therapeutics to a well-diversified portfolio.
Cynata Therapeutics Fundamentals Growth
Cynata Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cynata Therapeutics, and Cynata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cynata Pink Sheet performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X | |||
| Revenue | 7.77 M | |||
| EBITDA | (13.56 M) | |||
| Cash And Equivalents | 26.79 M | |||
| Cash Per Share | 0.19 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (3.3 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 26.55 M | |||
About Cynata Therapeutics Performance
By analyzing Cynata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cynata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cynata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cynata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Cynata Therapeutics performance evaluation
Checking the ongoing alerts about Cynata Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cynata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cynata Therapeutics generated a negative expected return over the last 90 days | |
| Cynata Therapeutics has some characteristics of a very speculative penny stock | |
| Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M. | |
| Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Roughly 15.0% of the company shares are held by company insiders |
- Analyzing Cynata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cynata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cynata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cynata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cynata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cynata Therapeutics' pink sheet. These opinions can provide insight into Cynata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cynata Pink Sheet analysis
When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |